Abstract
During the last decades, the pharmacotherapy of heart failure (HF) has changed dramatically. Large-scale trials have been conducted that have indisputably shown the efficacy of angiotensin-converting enzyme inhibitors (ACE-I) and beta-adrenergic receptor blockers (β-blockers). These and other therapies have improved the overall outcome of patients with HF, although prognosis remains bleak.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call